Topic: sterile injectables
Tidying up business left from last year, Bristol-Myers Squibb has completed the sale of an old-school operation in Italy.
Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.
Takeda has yet to seek approval for its vaccine candidate to treat dengue, but it now has a €130 million plant and 200 jobs relying on that nod.
Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.
Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin.
Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.
Novartis is expected to soon regain control of the Sandoz Boucherville sterile drug manufacturing site in Canada that it sold to Avara last year.
Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down.
Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.
An FDA warning letter for Akorn's New Jersey plant acknowledges efforts by management to turn things around but says it is not nearly enough.